Intellia Therapeutics, Inc., a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, has announced the pricing of an underwritten public offering of 5,479,453 shares of its common stock at a public offering price of US$18.25 per share. Intellia also granted the underwriters a 30-day option to purchase up to an additional 821,917 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be US$100 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Intellia.
Latham & Watkins LLP represents the underwriters in the transaction with a capital markets team led by partners Peter Handrinos and Nathan Ajiashvili, with associates Justin McNamee, Sandy Kugbei and Darby Dietrich.